Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient
- 170 Downloads
The treatment of cryptococcosis is hampered by inefficacy or intolerance to the recommended antifungal agents. A patient diagnosed with AIDS had multiple relapses of cryptococcal infection, which became refractory to antifungal agents during the course of therapy. During the follow-up, the patient developed renal toxicity due to amphotericin B use and non-susceptibility of isolated Cryptococcus neoformans to fluconazole was detected. Thereafter, antifungal treatment was performed exclusively with liposomal amphotericin B, reaching a cumulative dose of 19,180 mg over 46 months. The final relapse of cryptococcosis occurred during the maintenance phase with liposomal formulation in a once-weekly dose. Measurement of the minimum serum concentrations of amphotericin B, determined sequentially before and after this relapse, suggested the importance of monitoring drug levels when the liposomal formulation is used for a long period.
KeywordsCryptococcus Antifungal susceptibility Fluconazole Liposomal amphotericin B Cryptococcal meningitis
Letícia Aparecida Schiave received a scholarship from the São Paulo Research Foundation (FAPESP) related to the research project on the determination of amphotericin B levels (Grant # 2012/51030-4). Erika Nascimento performed the antifungal susceptibility tests. The Foundation of Support to Teaching, Research and Assistance of the University Hospital of the Ribeirão Preto Medical School, University of São Paulo (FAEPA) supported the disclosure of this study.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflicts of interest.
- 10.Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chondhary A, Cordoba S, et al. Cryptococcus neoformans–Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole and voriconazole. Antimicrob Agents Chemother. 2012;56(11):5898–906.CrossRefPubMedPubMedCentralGoogle Scholar